KPTI - Karyopharm falls 13% following late-stage results on selinexor for endometrial cancer

Although it met its primary endpoint, the results of a late-stage trial of Karyopharm's (NASDAQ:KPTI) Xpovio (selinexor) in endometrial cancer are being viewed as a disappointment. Shares are down 13% in premarket trading. The phase 3 trial is designed to support a supplemental new drug application for Xpovio. The drug is currently approved for multiple myeloma. Results released today found Selinexor-treated patients had a median progression-free survival ("PFS") of 5.7 months compared to 3.8 months for placebo patients, an improvement of 50%. This represents a 30% reduction in the risk of disease progression or death.  Data also showed that a subgroup of patients with wild-type p53 endometrial cancer had PFS of 13.7 months compared to 3.7 months for placebo, a 62% reduction in the risk of disease progression or death. Some on social media mentioned that the primary endpoint was achieved with a borderline p-value showing statistical significance. One Twitter user mentioned that

For further details see:

Karyopharm falls 13% following late-stage results on selinexor for endometrial cancer